MIMEDX Announces Record Revenue for Third Quarter 2025

Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History

Third QuarterNet Sales of$114 millionGrew35%Year-Over-Year

Third QuarterGAAP Net Income and Diluted Earnings Per Share were$17Million and$0.11, Respectively

Third QuarterAdjusted EBITDA was$35Million, or31%of Net Sales

Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations

Management to Host Conference Call Today, October 29, 2025,at 4:30 PM ET

MARIETTA, Ga., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the third quarter 2025.

Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "I am pleased to once again report another excellent quarterly financial performance for the Company. Third quarter 2025 net sales grew 35%, driven by double-digit growth in both our Wound and Surgical franchises. By capitalizing on various growth opportunities and continuing to drive efficiencies, we achieved the highest quarterly revenue, adjusted EBITDA and cash flow in the Company's history."

Mr. Capper continued, "As we await the final 2026 reimbursement rules from the Centers for Medicare and Medicaid Services (“CMS”), we are planning for a range of potential scenarios. We made certain recommendations to CMS during the comment period, which we believe will improve upon the proposed rules, if incorporated. Importantly, MIMEDX is well positioned to adapt, regardless of the outcome. We believe these reforms will have a much-needed stabilizing effect on our industry and are a net positive for US taxpayers, the Medicare Trust Fund, Medicare beneficiaries and for MIMEDX. As such, we continue to believe the long-term outlook for this Company is incredibly bright."

MIMEDX reported net sales for the three months ended September 30, 2025, of $114 million, compared to $84 million for the three months ended September 30, 2024, an increase of 35%. The increase was primarily driven by Wound product sales growth of 40% compared to the prior year period, driven by sales of our newer products, CELERA™ and EMERGE™. Additionally, net sales of our Surgical products increased 26% compared to the prior year period, including double-digit growth of our Surgical portfolio, including AMNIOFIX® and AMNIOEFFECT® and accelerating contributions from HELIOGEN®.

Gross profit for the three months ended September 30, 2025, was $95 million, compared to $69 million the prior year period. Gross margin for the three months ended September 30, 2025 was 84%, compared to 82% in the prior year period. The year-over-year increase in gross margin was driven primarily by product mix.

Selling, general and administrative ("SG&A") expenses for the three months ended September 30, 2025, were $69 million compared to $54 million for the three months ended September 30, 2024. The increase in SG&A was driven primarily by year-over-year increases in commissions.

Research and development ("R&D") expenses for the three months ended September 30, 2025 and 2024, were $4 million and $3 million, respectively. R&D spend in the quarter reflects the randomized controlled trial for EPIEFFECT® and ongoing investments in the development of future products in our pipeline.

Net income for the three months ended September 30, 2025 was $17 million compared to $8 million for the three months ended September 30, 2024.

As of September 30, 2025, the Company had $142 million of cash and cash equivalents compared to $104 million as of December 31, 2024. As of September 30, 2025, our cash position, net of debt on our balance sheet, was $124 million.

Financial OutlookFor 2025, MIMEDX now expects net sales growth to be in the mid-to-high teens as a percentage compared to 2024. 2025 Adjusted EBITDA margin is expected to be at least in the mid-20% range on a full year basis.

Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an adjusted EBITDA margin above 20%.

MIMEDX will host a conference call and webcast to review its third quarter 2025 results on Wednesday, October 29, 2025, beginning at 4:30 p.m., Eastern Time. The call can be accessed using the following information:

A replay of the webcast will be available for approximately 30 days on the Company’s website atwww.mimedx.comfollowing the conclusion of the event.

This press release includes forward-looking statements, including (i) statements regarding our 2025 and longer term financial goals and expectations for future financial results, including net sales growth and Adjusted EBITDA margin; and (ii) our expectations regarding the impact of CMS regulatory actions, including CMS’s 2026 reimbursement rules, on our financial results, outlook and industry. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," “goal,” “outlook,” "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations.

Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, the reimbursement environment and many other factors; (ii) the Company may change its plans due to unforeseen circumstances; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; (vi) we may alter the timing and amount of planned expenditures for research and development based on regulatory developments; (vii) changes in Medicare spending rules; (viii) changes in the size of the addressable market for our product; and (ix) continued market acceptance of our newer products, including CELERA and EMERGE, and continued uptake in demand for surgical products s. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA and related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income, Adjusted SG&A and Adjusted Earnings Per Share ("Adjusted EPS"). We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measures are not a substitute for GAAP measures. Company management uses these non-GAAP measures as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies.

These non-GAAP financial measures reflect the exclusion of the following items:

Adjusted EBITDA and Adjusted EBITDA margin

Adjusted EBITDA consists of GAAP net income excluding (i) share-based compensation, (ii) income tax provision, (iii) amortization of intangible assets (iv) strategic legal and regulatory expenses, (v) interest (income) expense, net, (vi) depreciation expense, (vii) reorganization expenses, (viii) transaction-related expenses, (ix) investigation, restatement and related expenses, (x) impairment of intangible assets , and (xi) expenses related to disbanding of Regenerative Medicine Business Unit.

A reconciliation of GAAP net income to Adjusted EBITDA appears in the table below (dollars in thousands):

Adjusted Net Income

Adjusted Net Income provides a view of our operating performance, exclusive of certain items which are non-recurring or not reflective of our core operations.

Adjusted Net Income is defined as GAAP net income plus (i) amortization of acquired intangible assets, (ii) strategic legal and regulatory expenses, (iii) reorganization expenses, (iv) transaction related expenses, (v) investigation, restatement and related expense (benefit), (vi) loss on extinguishment of debt, (vii) expenses related to disbanding of Regenerative Medicine business unit, (viii) impairment of intangible assets, and (ix) the long-term effective income tax rate adjustment.

A reconciliation of GAAP net income to Adjusted Net Income appears in the table below (in thousands):

A reconciliation of various line items included in our GAAP unaudited condensed consolidated statements of operations to Adjusted Net Income for the three months ended September 30, 2025 and 2024 are presented in the tables below (in thousands):

Adjusted Earnings Per Share is intended to provide a normalized view of earnings per share by removing items that may be irregular, one-time, or non-recurring from net income. This enables us to identify underlying trends in our business that could otherwise be masked by such items. Adjusted Earnings Per Share consists of GAAP diluted net income per common share including adjustments for (i) loss on extinguishment of debt, (ii) investigation restatement and related benefit, (iii) impairment of intangible assets, (iv) amortization of acquired intangible assets, (v) strategic legal and regulatory expenses, (vi) transaction-related expenses, (vii) expenses related to disbanding of our Regenerative Medicine business unit, (viii) reorganization expenses, and (ix) the long-term effective income tax rate adjustment.

A reconciliation of GAAP diluted earnings per share to Adjusted Earnings Per Share appears in the table below (per diluted share):

Free Cash Flow is intended to provide a measure of our ability to generate cash in excess of capital investments. It provides management with a view of cash flows which can be used to finance operational and strategic investments.

Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, including purchases of equipment.

A reconciliation of GAAP net cash flows provided by operating activities to Free Cash Flow appears in the table below (in thousands):

Net Sales by Product Category by Quarter

Below is a summary of net sales by product category (in thousands):